Home » Stocks » MYGN

Myriad Genetics, Inc. (MYGN)

Stock Price: $30.95 USD 0.46 (1.51%)
Updated Mar 1, 2021 10:36 AM EST - Market open
Market Cap 2.30B
Revenue (ttm) 597.50M
Net Income (ttm) -194.10M
Shares Out 74.70M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE 625.00
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $30.95
Previous Close $30.49
Change ($) 0.46
Change (%) 1.51%
Day's Open 31.15
Day's Range 30.21 - 31.30
Day's Volume 97,013
52-Week Range 9.24 - 31.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 5 days ago

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

Zacks Investment Research - 5 days ago

Myriad (MYGN) delivered earnings and revenue surprises of 0.00% and 4.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 days ago

Shares of Myriad Genetics (NASDAQ:MYGN) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 152.17% over the past year ...

GlobeNewsWire - 5 days ago

Highlights:

GlobeNewsWire - 1 week ago

New talent and promotions span core businesses, transformation, IT, revenue cycle management, business development, marketing, legal New talent and promotions span core businesses, transformat...

GlobeNewsWire - 1 week ago

SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will hold its quarterly earnings c...

Zacks Investment Research - 1 week ago

Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.

GlobeNewsWire - 2 weeks ago

Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those ...

GlobeNewsWire - 2 weeks ago

SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple...

Zacks Investment Research - 2 weeks ago

Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.

GlobeNewsWire - 3 weeks ago

New Analysis Published in Psychiatry Research

GlobeNewsWire - 3 weeks ago

SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine...

Zacks Investment Research - 1 month ago

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

Patients with Prostate or Pancreatic Cancer to Benefit  from Treatment with Lynparza

PRNewsWire - 1 month ago

NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

Zacks Investment Research - 1 month ago

Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.

Other stocks mentioned: ILMN
GlobeNewsWire - 1 month ago

Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following di...

GlobeNewsWire - 1 month ago

SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimburse...

CNBC - 1 month ago

These are the stocks posting the largest moves after hours on Tuesday.

Other stocks mentioned: CALM, NKTR, SGH
GlobeNewsWire - 1 month ago

Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth

GlobeNewsWire - 1 month ago

SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discus...

GlobeNewsWire - 2 months ago

SALT LAKE CITY, Dec. 11, 2020 (GLOBE NEWSWIRE) -- In a spotlight poster discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS), Myriad Genetics (NASDAQ: MYGN), a global leader in m...

Zacks Investment Research - 2 months ago

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Investors Business Daily - 2 months ago

Myriad Genetics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: Myriad Genetics Flashes Improved Technical Strength appeare...

PRNewsWire - 3 months ago

FRESNO, Calif., Nov. 30, 2020 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, has signed a contract with Myriad Genetics, Inc. (...

GlobeNewsWire - 3 months ago

New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it” New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it”

GlobeNewsWire - 3 months ago

SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad...

GlobeNewsWire - 3 months ago

SALT LAKE CITY, Nov. 11, 2020 (GLOBE NEWSWIRE) -- At the annual meeting of the American College of Rheumatology (ACR), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics a...

Zacks Investment Research - 3 months ago

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

Seeking Alpha - 3 months ago

Myriad Genetics' (MYGN) CEO Paul Diaz on Q1 2021 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Myriad (MYGN) delivered earnings and revenue surprises of 54.55% and 7.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

SALT LAKE CITY, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earn...

Zacks Investment Research - 4 months ago

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

GlobeNewsWire - 4 months ago

SALT LAKE CITY, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the company has fi...

Zacks Investment Research - 5 months ago

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 5 months ago

Rashmi Kumar Elected to Myriad’s Board of Directors Rashmi Kumar Elected to Myriad’s Board of Directors

Zacks Investment Research - 5 months ago

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

Other stocks mentioned: ABT, GE, MDT, ZBH
Zacks Investment Research - 6 months ago

Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.

GlobeNewsWire - 6 months ago

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the American Soc...

GlobeNewsWire - 6 months ago

SALT LAKE CITY, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today anno...

Zacks Investment Research - 6 months ago

Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.

The Motley Fool - 6 months ago

But there were a few encouraging signs for the molecular-diagnostics company.

Seeking Alpha - 6 months ago

Myriad Genetics (MYGN) Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Myriad (MYGN) delivered earnings and revenue surprises of 13.89% and -2.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

CNBC - 6 months ago

These are the stocks posting the largest moves after the bell Thursday.

Other stocks mentioned: AMAT, BIDU, FTCH
Benzinga - 6 months ago

Shares of Myriad Genetics (NASDAQ:MYGN) moved higher by 1.64% in after-market trading after the company reported Q4 results.

GlobeNewsWire - 6 months ago

SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today anno...

GlobeNewsWire - 6 months ago

SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today ann...

Benzinga - 6 months ago

On Thursday, August 13, Myriad Genetics (NASDAQ: MYGN) will report its last quarter's earnings.

About MYGN

Myriad Genetics, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with delet... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 5, 1995
CEO
R. Bryan Riggsbee
Employees
2,700
Stock Exchange
NASDAQ
Ticker Symbol
MYGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is 26.00, which is a decrease of -15.99% from the latest price.

Price Target
$26.00
(-15.99% downside)
Analyst Consensus: Hold